Research On Financial Risk Control-A Case Study Of A Company

"Made in China 2025" has made it clear that the pharmaceutical industry will be one of the ten key development industries in China,the core industrial area of innovation country.Pharmaceutical r&d "high input,long cycle,high risk" features,become a key for the further development of private medical enterprise progress.For private pharmaceutical enterprises,the typical family background often has problems such as weak r&d ability,low technology content and financing difficulty.Capital has a great demand for the development of private enterprises,and the enterprises usually take bank loans to solve the capital problem.However,Banks restrict the lending policies of private enterprises.If they need to provide collateral or guarantee,and the financial cost burden of the enterprises themselves,they will increase the financial risk of pharmaceutical enterprises to a certain extent.Company A was established in Shenzhen in 2008 and is A typical private pharmaceutical company.At high speed in the last decade,the occurrence of financial risks due to mismanagement can influence the sustainable development of A company.Based on A company as the research object,this paper aimed at A company faces financial risk analysis by 2014-2016,and in the form of A questionnaire to survey the problem of the control system,found in A company financing,capital collection,liquidity,research and development are facing A certain financial risk,and control system and there are some defects in the design and operation.In view of these defects,we put forward the optimization design plan from the financial control environment,financial risk identification and evaluation system,financial risk response and financial risk supervision system of company A,and put forward the safeguard measures from the management level and business execution level of the enterprise to ensure the smooth implementation of the plan.